美股异动 | 获两大药企争夺收购 Avadel Pharmaceuticals(AVDL.US)涨超20%

Core Viewpoint - Avadel Pharmaceuticals' stock surged over 20% following an unsolicited acquisition proposal from Lundbeck, offering up to $23 per share, which is higher than Alkermes' previous offer of $20 per share [1] Group 1: Company Developments - Avadel Pharmaceuticals' stock price reached $23.215 after the announcement of the acquisition proposal [1] - Lundbeck's offer of up to $23 per share is significantly higher than the previous offer from Alkermes, which was capped at $20 per share [1] - Despite the positive market reaction, Avadel's board has not yet determined if Lundbeck's proposal is superior to Alkermes' offer and has not changed its recommendation regarding the Alkermes acquisition [1]